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TO THE EDITORS:
The recent study by Kashyap et al.1 conﬁrmed with a
large, single-center experience that donors with central
nervous system (CNS) tumors should be proposed for
liver donation, as we recently advocated.2 In their se-
ries of 42 liver donors with CNS tumors and a mean fol-
low-up of 29 months, 20 donors had grade IV astrocy-
toma or glioblastoma multiforme, and none of the
recipients developed recurrence of these aggressive
tumors. Kashyap et al. observed 1 case of metastatic
recurrence of the donor CNS cancer, which was a juve-
nile pilocytic astrocytoma of the cervical spinal cord.
The real risk of CNS cancer transmission with liver
transplantation is not known. It may vary according
to the aggressiveness of the CNS cancer (histology),
the previous treatments (radiotherapy, open skull
surgery, and shunting), and the length of the delay
between the diagnosis of the CNS cancer and brain
death.3 It may also vary according to the recipient’s
immunosuppression, because calcineurin inhibitors
have demonstrated an effect on cancerous cell activa-
tion.4 The transmission risk has been largely overesti-
mated by the Israel Penn International Transplant Tu-
mor Registry (IPITTR). The IPITTR estimated this risk
to be as high as 40% with grade III/IV astrocytoma.5
This overestimation is related to the nature of this vol-
untary and retrospective registry. The transmission
risk should be scientiﬁcally determined from the ratio
of the number of patients who have experienced
transmission to the entire population of patients at
risk, and it is likely that the IPITTR lacks important
information on the denominator of this ratio.2 The
IPITTR and isolated case reports6,7 are responsible for
the negative reputation of donors with CNS cancers.8
Prospective, multicenter registries9 and some large,
single-center experiences, such as Kashyap et al.’s
study,1 have demonstrated that the risk of CNS can-
cer transmission should be evaluated as 0% to 3%,
and these data have to be better deﬁned by further
prospective, large-scale registries.3 In comparison
with the actual, unacceptable death rates on the
liver waiting lists, which have led to the development
of living related liver transplantation and its 0.5%
donor mortality risk10 and transplant tourism,11 this
risk of CNS cancer transmission with liver transplan-
tation may seem acceptable, especially for fully
informed patients who have a high risk of death on
the waiting lists. Organ transplantation carries a
small but real risk of occult cancer transmission
anyway.12,13
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